Amgen Finally Reaches Deal to Buy Onyx Pharmaceuticals, Inc. for $10.4 Billion, AMGN Stock Rockets +7.72% on Monday @ Market Close (August 26, 2013)

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Although Amgen is the world’s biggest biotechnology company, the drug maker has been mostly absent from one of the industry’s biggest and fastest-growing markets: cancer drugs. It took a big step to fix that on Sunday, agreeing to buy Onyx Pharmaceuticals for about $10.4 billion in cash to gain access to the company’s three anticancer treatments. Under the terms of Sunday’s deal, Amgen will offer $125 a share in cash through a tender offer for Onyx’s shares.

Help employers find you! Check out all the jobs and post your resume.

Back to news